EUVIMEDEUVIMED entdecken
Crossref

Long non-coding RNA MSC-AS1 confers imatinib resistance of gastrointestinal stromal tumor cells by activating FNDC1 and ANLN-mediated PI3K/AKT pathway

Lin Chen, Yongjian Gao, Huaixi Yang, Yanzhuo Su, Yunxin Zhang, Lin Lou, Xuefeng Wang, Dayong Ding

Human Cell · 2025

DOI: 10.1007/s13577-024-01167-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Cell, 2025. Verfasst von Lin Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal and Colorectal Surgery, China-Japan Union Hospital of Jilin University, No. 126 Sendai Street, Nanguan District, Chang…. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Imatinib Mesylate, Drug Resistance, Neoplasm, RNA, Long Noncoding. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Natural Science Foundation of Jilin Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Imatinib resistance is a major obstacle to the successful treatment of gastrointestinal stromal tumors (GIST). Long non-coding RNAs (LncRNAs) have been identified as important regulatory factors in chemotherapy resistance. This study aimed to identify key lncRNAs involved in imatinib resistance of GISTs. First, MSC-AS1 was found to be upregulated in imatinib-resistant GIST tissues and imatinib-resistant GIST cells. Cellular experiments demonstrated that MSC-AS1 overexpression decreased imatinib sensitivity of GIST cells, evidenced by increased cell survival, colony formation, migration, and invasion. Moreover, suppression of MSC-AS1 improved the imatinib resistance of imatinib-resistant GIST cells. Furthermore, MSC-AS1 upregulated the expression of FNDC1 and Anillin via sponging miR-200b-3p, activated the phosphatidylinositol-3-kinase-AKT signaling pathway, and thereby driving imatinib resistance in vitro and in vivo. Overall, this study elucidates the crucial role and mechanism of MSC-AS1 in the imatinib resistance of GIST, providing the potential therapeutic strategy for overcoming the imatinib resistance of GIST.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal Stromal TumorsImatinib MesylateDrug Resistance, NeoplasmRNA, Long NoncodingProto-Oncogene Proteins c-aktSignal TransductionHumansPhosphatidylinositol 3-KinasesAntineoplastic AgentsGastrointestinal NeoplasmsCell Line, TumorFibronectinsGene ExpressionMicroRNAsMicrofilament ProteinsUp-RegulationPhosphatidylinositol 3-Kinase

Stichwörter der Autor:innen

Gastrointestinal stromal tumorsImatinib resistanceLong noncoding RNA

Substanzen

Imatinib MesylateRNA, Long NoncodingProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesAntineoplastic AgentsFibronectinsMicroRNAsMIRN200 microRNA, humanMicrofilament ProteinsPhosphatidylinositol 3-Kinase

Autor:innen und Institutionen

  • Department of Gastrointestinal and Colorectal Surgery, China-Japan Union Hospital of Jilin University, No. 126 Sendai Street, Nanguan District, Changchun, 130031, China.
  • Department of Gastrointestinal and Colorectal Surgery, China-Japan Union Hospital of Jilin University, No. 126 Sendai Street, Nanguan District, Changchun, 130031, China. dingdy@jlu.edu.cn.

Förderung

  • Natural Science Foundation of Jilin Province

Zitieren

APA

Chen, L., Gao, Y., Yang, H., Su, Y., Zhang, Y., Lou, L., Wang, X., & Ding, D. (2025). Long non-coding RNA MSC-AS1 confers imatinib resistance of gastrointestinal stromal tumor cells by activating FNDC1 and ANLN-mediated PI3K/AKT pathway. Human Cell. https://doi.org/10.1007/s13577-024-01167-7

Vancouver

Chen L, Gao Y, Yang H, Su Y, Zhang Y, Lou L, et al. Long non-coding RNA MSC-AS1 confers imatinib resistance of gastrointestinal stromal tumor cells by activating FNDC1 and ANLN-mediated PI3K/AKT pathway. Human Cell. 2025. doi:10.1007/s13577-024-01167-7

BibTeX
@article{Chen2025,
  author = {Chen, Lin and Gao, Yongjian and Yang, Huaixi and Su, Yanzhuo and Zhang, Yunxin and Lou, Lin and Wang, Xuefeng and Ding, Dayong},
  title = {Long non-coding RNA MSC-AS1 confers imatinib resistance of gastrointestinal stromal tumor cells by activating FNDC1 and ANLN-mediated PI3K/AKT pathway},
  journal = {Human Cell},
  year = {2025},
  doi = {10.1007/s13577-024-01167-7}
}
Kostenlos starten →